Capecitabine + Sunitinib
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Breast Cancer
Conditions
Advanced/Metastatic Breast Cancer
Trial Timeline
Apr 1, 2008 → May 1, 2012
NCT ID
NCT00662025About Capecitabine + Sunitinib
Capecitabine + Sunitinib is a phase 2 stage product being developed by Pfizer for Advanced/Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00662025. Target conditions include Advanced/Metastatic Breast Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Breast Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00662025 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced/Metastatic Breast Cancer